Oncolytics Biotech secured a new U.S. patent on June 16, 2026, covering the commercial manufacturing process of its cancer immunotherapy pelareorep [1], [2], [4].

This intellectual property grant is critical because it protects the company's ability to scale the production of its primary drug candidate. By securing the unique manufacturing process, the company prevents competitors from replicating the production method while it pursues commercialization.

The patent extends protection for the commercial manufacturing of pelareorep into 2044 [1], [3]. This adds a significant layer of security to the company's intellectual property estate, ensuring that the scalable process remains proprietary for nearly two decades.

Pelareorep is an investigational immunotherapy designed to treat cancer. The company is utilizing this patent to safeguard the specific methods used to create the drug at a commercial scale, a step necessary for moving from clinical trials to widespread market availability.

This new grant complements other protections already in place. The company's method-of-use patent protection is expected to run until 2046 [1]. By layering manufacturing patents with use patents, the company creates a broader barrier to entry for generic competitors.

Oncolytics Biotech, which is headquartered in San Diego, California, intends to continue expanding its legal protections [1], [2]. The company has planned additional patent filings for 2026 [1].

These strategic filings are intended to maximize the commercial value of the drug candidate. The company is listed on the Nasdaq under the ticker ONCY [1].

“The new patent protects the commercial production of pelareorep through 2044.”

Securing a manufacturing patent is a strategic move to prevent 'biosimilar' or generic competition. While a method-of-use patent prevents others from using a drug for a specific purpose, a manufacturing patent protects how the drug is actually made. For a clinical-stage company like Oncolytics Biotech, this reduces the risk that a competitor could develop a cheaper, alternative production method to undercut them once the drug reaches the market.